Victoza vs. Farxiga

See how Victoza and Farxiga compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Victoza is a once-daily injectable GLP-1 that also lowers cardiovascular risk, while Farxiga is a once-daily pill that also protects the heart and kidneys.

  • Victoza's most common side effects are gastrointestinal, while Farxiga's are mostly genital and urinary infections.

  • Both treat type 2 diabetes, but Farxiga has broader FDA approvals covering heart failure and chronic kidney disease on their own.

Victoza vs. Farxiga Drug Summary

Victoza

Victoza (liraglutide) is a GLP-1 receptor agonist used to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It also carries an approval to reduce major cardiovascular events in people with type 2 diabetes and heart disease. It is given as a once-daily injection under the skin, with a dose that increases over the first few weeks.

Farxiga

Farxiga (dapagliflozin) is an SGLT2 inhibitor used to control blood sugar in adults and children 10 and older with type 2 diabetes. It is also approved for heart failure and chronic kidney disease, independent of diabetes status. It comes as a once-daily oral tablet, typically started at a single dose without titration.

Victoza vs. Farxiga Side Effects

Victoza

Most common
Diarrhea (up to 11.7%)
Nausea (≥5%)
Vomiting (≥5%)
Decreased appetite (≥5%)

Farxiga

Most common
Female genital mycotic infections (6.9%)
Nasopharyngitis (6.3%)
Urinary tract infections (4.3%)
Back pain (4.2%)

Victoza vs. Farxiga Dosage

Victoza

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.6 mg once daily Week 1
Maximum dose 1.8 mg once daily Week 3 onward
Dose changes 2 increases Every week

Farxiga

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once daily At the start
Maximum dose 10 mg once daily If needed
Dose changes 1 increase As tolerated

Victoza vs. Farxiga Indications

Victoza

Victoza is FDA-approved to improve blood sugar control alongside diet and exercise in type 2 diabetes, including in children 10 and older. It also carries a specific approval to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and existing heart disease. It is not approved for type 1 diabetes.

  • Type 2 diabetes glycemic control (adults and children 10+)

  • Reduce risk of major cardiovascular events in established heart disease

  • Basis for Saxenda, a higher-dose version for weight management

  • Not approved for type 1 diabetes

Farxiga

Farxiga is FDA-approved for blood sugar control in type 2 diabetes, including children 10 and older, but its approvals extend well beyond diabetes. It is also approved to reduce heart failure hospitalization, treat heart failure directly, and slow chronic kidney disease progression. It is not approved for type 1 diabetes or diabetic ketoacidosis.

  • Type 2 diabetes glycemic control (adults and children 10+)

  • Reduce hospitalization risk for heart failure patients

  • Slow chronic kidney disease progression and failure

  • Not approved for type 1 diabetes or ketoacidosis

Victoza vs. Farxiga Pros and Cons

Victoza

Victoza has a long track record and proven cardiovascular benefit in people with existing heart disease, but it requires a daily injection and carries a boxed warning for thyroid tumor risk seen in animal studies. Coverage varies and list price runs higher than many oral diabetes options.

Pros

  • Proven to reduce cardiovascular events in high-risk patients

  • Often supports modest weight loss alongside glucose control

  • Approved for pediatric type 2 diabetes down to age 10

Cons

  • Daily injection, unlike oral alternatives

  • Boxed warning for thyroid C-cell tumor risk

  • Higher typical monthly list price, roughly $935 to $1,470 without insurance

  • GI side effects like nausea and vomiting are common early on

Farxiga

Farxiga is taken as a simple once-daily pill with no titration and has FDA approvals spanning heart failure and chronic kidney disease beyond diabetes. Its main risks are genital and urinary infections rather than gastrointestinal upset, and it is less suitable for people with significant kidney impairment.

Pros

  • Once-daily oral pill with no dose titration needed

  • Approved for heart failure and chronic kidney disease independent of diabetes

  • Lower typical monthly list price, roughly $400 to $785 without insurance

Cons

  • Risk of genital and urinary tract infections

  • Rare but serious risk of Fournier's gangrene

  • Not recommended for glycemic control at low kidney function levels

  • Risk of ketoacidosis even with near-normal blood sugar

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.